Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 extension study of UTTR1147A in ulcerative colitis or Crohn's disease
MOH_2019-01-20_004923Phase 2Not yet recruiting
- Sponsor
- Genentech
- Start
- Jan 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efmarodocokin alfa in autoimmune colitis, Crohn's disease and inflammatory bowel disease (IBD), sponsored by Genentech. Primary endpoints: Long-term safety of UTTR1147A and Long-term tolerability of UTTR1147A. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
efmarodocokin alfa
03
Conditions
autoimmune colitisCrohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on MOH_2019-01-20_004923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-01-20_004923.